Yesterday, the Facilities for Medicare and Medicaid Companies (CMS) issued a draft National Coverage Resolve (NCD) proposing that monoclonal antibodies directed against amyloid for the
Yesterday, the Facilities for Medicare and Medicaid Companies (CMS) issued a draft National Coverage Resolve (NCD) proposing that monoclonal antibodies directed against amyloid for the
